BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 16235179)

  • 1. Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy.
    Casula M; Weverling GJ; Wit FW; Timmermans EC; Stek M; Lange JM; Reiss P
    J Infect Dis; 2005 Nov; 192(10):1794-800. PubMed ID: 16235179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients.
    Maagaard A; Holberg-Petersen M; Kvittingen EA; Sandvik L; Bruun JN
    HIV Med; 2006 Jan; 7(1):53-8. PubMed ID: 16313293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy.
    Miura T; Goto M; Hosoya N; Odawara T; Kitamura Y; Nakamura T; Iwamoto A
    J Med Virol; 2003 Aug; 70(4):497-505. PubMed ID: 12794710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study.
    Rabing Christensen E; Stegger M; Jensen-Fangel S; Laursen AL; Ostergaard L
    Clin Infect Dis; 2004 Nov; 39(9):1371-9. PubMed ID: 15494915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial).
    Feeney ER; Chazallon C; O'Brien N; Meiffrédy V; Goodall RL; Aboulker JP; Cooper DA; Yeni P; Mallon PW;
    HIV Med; 2011 Nov; 12(10):602-9. PubMed ID: 21599820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients.
    Maagaard A; Holberg-Petersen M; Kollberg G; Oldfors A; Sandvik L; Bruun JN
    Antivir Ther; 2006; 11(5):601-8. PubMed ID: 16964828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment.
    Maagaard A; Holberg-Petersen M; Løvgården G; Holm M; Pettersen FO; Kvale D
    J Infect Dis; 2008 Nov; 198(10):1474-81. PubMed ID: 18851688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
    Rosso R; Nasi M; Di Biagio A; Repetto E; Dentone C; Pinti M; Nemes E; Ferraresi R; Mussini C; Esposito R; Viscoli C; Cossarizza A
    Pediatr Infect Dis J; 2008 Jan; 27(1):17-21. PubMed ID: 18162932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal effects of thymidine analogues on mtDNA, mtRNA and multidrug resistance (MDR-1) induction in cultured cells.
    Papp E; Gadawski I; Côté HC
    J Antimicrob Chemother; 2008 May; 61(5):1048-52. PubMed ID: 18310046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
    De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
    Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV-infected patients with lipodystrophy according to a validated case definition.
    Casula M; van der Valk M; Wit FW; Nievaard MA; Reiss P
    HIV Med; 2007 Jan; 8(1):32-7. PubMed ID: 17305930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
    Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
    J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
    Milinkovic A; Martinez E; López S; de Lazzari E; Miró O; Vidal S; Blanco JL; Garrabou G; Laguno M; Arnaiz JA; Leon A; Larrousse M; Lonca M; Mallolas J; Gatell JM
    Antivir Ther; 2007; 12(3):407-15. PubMed ID: 17591031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.
    van der Valk M; Casula M; Weverlingz GJ; van Kuijk K; van Eck-Smit B; Hulsebosch HJ; Nieuwkerk P; van Eeden A; Brinkman K; Lange J; de Ronde A; Reiss P
    Antivir Ther; 2004 Jun; 9(3):385-93. PubMed ID: 15259901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.
    Mallon PW; Unemori P; Sedwell R; Morey A; Rafferty M; Williams K; Chisholm D; Samaras K; Emery S; Kelleher A; Cooper DA; Carr A;
    J Infect Dis; 2005 May; 191(10):1686-96. PubMed ID: 15838796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
    Sievers M; Walker UA; Sevastianova K; Setzer B; Wågsäter D; Eriksson P; Yki-Järvinen H; Sutinen J
    J Infect Dis; 2009 Jul; 200(2):252-62. PubMed ID: 19519254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.
    Miró O; Villarroya J; Garrabou G; López S; Rodríguez de la Concepción M; Pedrol E; Martínez E; Giralt M; Gatell JM; Cardellach F; Casademont J; Villarroya F
    Antivir Ther; 2005; 10(8):945-51. PubMed ID: 16430200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constant mitochondrial DNA levels in blood leukocytes of patients enrolled in a NRTI-free therapeutic trial (BIKS-2 study).
    Amellal B; Allavena C; André-Garnier E; Ferré V; Valantin MA; Delfraissy JF; Lafeuillade A; Bonmarchand M; Calvez V; Raffi F
    J Infect; 2007 Jun; 54(6):603-8. PubMed ID: 17207857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.